Literature DB >> 7811013

Ticarcillin-clavulanic acid pharmacokinetics in preterm neonates with presumed sepsis.

A H Burstein1, L E Wyble, P Gal, P R Diaz, J L Ransom, R Q Carlos, A Forrest.   

Abstract

The objective of the reported study was to characterize the pharmacokinetics of ticarcillin and clavulanic acid in premature low-birth-weight (less than 2,200 g) neonates with presumed sepsis. Eleven infants received 12 courses of ticarcillin-clavulanic acid at 75 mg/kg of body weight intravenously every 12 h. Blood samples were collected at 0.5, 1.5, 4, and 8 h following the infusion of the initial dose. The concentrations of ticarcillin and clavulanic acid were determined by a microbiologic assay. Median (interpatient coefficients of variation) values for the volume of the central compartment, total steady-state volume, distributional clearance, total clearance, and terminal elimination half-life for ticarcillin were 0.030 liter/kg (21%), 0.26 liter/kg (48%), 0.41 liter/h/kg (47%), 0.047 liter/h/kg (47%), and 4.2 h (45%), respectively. For clavulanic acid the parameters were 0.28 liter/kg (32%), 0.36 liter/kg (34%), 11 liters/h/kg (36%), 0.12 liters/h/kg (72%), and 1.95 h (40%), respectively. Our results suggest that the current dosing recommendations of 75 mg/kg every 12 h risk subtherapeutic clavulanic acid concentrations and that 50 mg/kg every 6 h is a more rational dosing strategy.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7811013      PMCID: PMC284678          DOI: 10.1128/AAC.38.9.2024

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  13 in total

1.  The prophylactic use of ticarcillin/clavulanate in the neonate.

Authors:  S B Fayed; A M Sutton; T L Turner; T A McAllister
Journal:  J Antimicrob Chemother       Date:  1987-01       Impact factor: 5.790

2.  Bioavailability and pharmacokinetics of clavulanic acid in healthy subjects.

Authors:  B E Davies; P E Coates; J G Clarke; A R Thawley; J A Sutton
Journal:  Int J Clin Pharmacol Ther Toxicol       Date:  1985-02

Review 3.  Pharmacokinetics and drug distribution during postnatal development.

Authors:  B M Assael
Journal:  Pharmacol Ther       Date:  1982       Impact factor: 12.310

4.  Optimal sampling times for pharmacokinetic experiments.

Authors:  D Z D'Argenio
Journal:  J Pharmacokinet Biopharm       Date:  1981-12

5.  A simplified score for assessment of fetal maturation of newly born infants.

Authors:  J L Ballard; K K Novak; M Driver
Journal:  J Pediatr       Date:  1979-11       Impact factor: 4.406

6.  The pharmacokinetics of ticarcillin/clavulanate acid in neonates.

Authors:  G Fricke; M Doerck; D Hafner; R Horton; M Kresken
Journal:  J Antimicrob Chemother       Date:  1989-11       Impact factor: 5.790

7.  Kinetic studies on the inactivation of Escherichia coli RTEM beta-lactamase by clavulanic acid.

Authors:  J Fisher; R L Charnas; J R Knowles
Journal:  Biochemistry       Date:  1978-05-30       Impact factor: 3.162

8.  Antibacterial activity of ticarcillin in the presence of clavulanate potassium.

Authors:  R Sutherland; A S Beale; R J Boon; K E Griffin; B Slocombe; D H Stokes; A R White
Journal:  Am J Med       Date:  1985-11-29       Impact factor: 4.965

9.  An evaluation of optimal sampling strategy and adaptive study design.

Authors:  G L Drusano; A Forrest; M J Snyder; M D Reed; J L Blumer
Journal:  Clin Pharmacol Ther       Date:  1988-08       Impact factor: 6.875

10.  Development of a population pharmacokinetic model and optimal sampling strategies for intravenous ciprofloxacin.

Authors:  A Forrest; C H Ballow; D E Nix; M C Birmingham; J J Schentag
Journal:  Antimicrob Agents Chemother       Date:  1993-05       Impact factor: 5.191

View more
  7 in total

1.  Population pharmacokinetics of arbekacin, vancomycin, and panipenem in neonates.

Authors:  Toshimi Kimura; Keisuke Sunakawa; Nobuo Matsuura; Hiroaki Kubo; Shigehiko Shimada; Kazuo Yago
Journal:  Antimicrob Agents Chemother       Date:  2004-04       Impact factor: 5.191

Review 2.  Clinical pharmacokinetics of penicillins in the neonate: a review of the literature.

Authors:  G M Pacifici; J Labatia; H Mulla; I Choonara
Journal:  Eur J Clin Pharmacol       Date:  2008-09-23       Impact factor: 2.953

3.  Pharmacokinetics of ticarcillin-clavulanate in premature infants.

Authors:  Kevin M Watt; Christoph P Hornik; Stephen J Balevic; Gratias Mundakel; C Michael Cotten; Barrie Harper; Daniel K Benjamin; Ravinder Anand; Matthew Laughon; P Brian Smith; Michael Cohen-Wolkowiez
Journal:  Br J Clin Pharmacol       Date:  2019-03-06       Impact factor: 4.335

Review 4.  Antibiotics in neonatal infections: a review.

Authors:  V Fanos; A Dall'Agnola
Journal:  Drugs       Date:  1999-09       Impact factor: 9.546

5.  Pharmacokinetics of Commonly Used Medications in Children Receiving Continuous Renal Replacement Therapy: A Systematic Review of Current Literature.

Authors:  Samuel Dubinsky; Kevin Watt; Steven Saleeb; Bilal Ahmed; Caitlin Carter; Cindy H T Yeung; Andrea Edginton
Journal:  Clin Pharmacokinet       Date:  2021-11-30       Impact factor: 6.447

Review 6.  Clinical Pharmacokinetics of Penicillins, Cephalosporins and Aminoglycosides in the Neonate: A Review.

Authors:  Gian Maria Pacifici
Journal:  Pharmaceuticals (Basel)       Date:  2010-08-12

7.  Pharmacokinetics of Clavulanic Acid in the Pediatric Population: A Systematic Literature Review.

Authors:  Fleur M Keij; Gerdien A Tramper-Stranders; Birgit C P Koch; Irwin K M Reiss; Anouk E Muller; René F Kornelisse; Karel Allegaert
Journal:  Clin Pharmacokinet       Date:  2022-03-31       Impact factor: 5.577

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.